Publication Date
| In 2025 | 1 |
| Since 2024 | 2 |
| Since 2021 (last 5 years) | 2 |
| Since 2016 (last 10 years) | 2 |
| Since 2006 (last 20 years) | 3 |
Descriptor
| Attention Deficit… | 3 |
| Correlation | 3 |
| Drug Therapy | 3 |
| Predictor Variables | 3 |
| Stimulants | 3 |
| Adults | 2 |
| Outcomes of Treatment | 2 |
| Age Differences | 1 |
| Child Health | 1 |
| Clinical Diagnosis | 1 |
| Comorbidity | 1 |
| More ▼ | |
Source
| Journal of Attention Disorders | 3 |
Author
| Allison Green | 1 |
| Arnold, L. Eugene | 1 |
| Bukstein, Oscar G. | 1 |
| Caroline Kelberman | 1 |
| Curtis Bone | 1 |
| Destin Groff | 1 |
| Faraone, Stephen V. | 1 |
| Findling, Robert L. | 1 |
| Glatt, Stephen J. | 1 |
| James Capella | 1 |
| James R. Latronica | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 3 |
| Reports - Research | 2 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkYuwen Hung; Allison Green; Caroline Kelberman; Schuyler Gaillard; James Capella; Nicole Rudberg; John D. E. Gabrieli; Joseph Biederman; Mai Uchida – Journal of Attention Disorders, 2024
Objective: Stimulant medications are the main treatment for Attention Deficit Hyperactivity Disorder (ADHD), but overall treatment efficacy in adults has less than a 60% response rate. This study aimed to identify neural and cognitive markers predictive of longitudinal improvement in response to stimulant treatment in drug-naïve adults with ADHD.…
Descriptors: Stimulants, Drug Therapy, Attention Deficit Hyperactivity Disorder, Adults
Destin Groff; Wen-Jan Tuan; Kraig Holt; James R. Latronica; Curtis Bone – Journal of Attention Disorders, 2025
Introduction: Prescription stimulants are an effective FDA approved treatment for attention deficit hyperactivity disorder (ADHD) however their safety has come under scrutiny. Multiple studies demonstrate safe use in pediatric populations, but prescriptions are increasing to adults and it is not evident which comorbidities might place people at…
Descriptors: Heart Disorders, Stimulants, Attention Deficit Hyperactivity Disorder, Drug Therapy
Faraone, Stephen V.; Glatt, Stephen J.; Bukstein, Oscar G.; Lopez, Frank A.; Arnold, L. Eugene; Findling, Robert L. – Journal of Attention Disorders, 2009
Objective: Methylphenidate is a leading first-line treatment for ADHD (AD/HD). This stimulant has long been suspected to adversely affect sleeping patterns of treated individuals, especially children. There are few studies on the effects of recently developed longer-acting methylphenidate treatments, such as once-daily oral or transdermal…
Descriptors: Sleep, Attention Deficit Hyperactivity Disorder, Severity (of Disability), Drug Therapy
